TSHA Taysha Gene Therapies, Inc. Insider Trading

Nagendran Sukumar (President and Head of R&D) sold 200,000 shares of TSHA at $4.46 for $892,000.00

On 2026-04-10, Nagendran Sukumar sold 200,000 shares at $4.46, reducing his holdings from 1,336,410 shares to 1,136,410 shares. The current price of $4.42 is -25.2% from the 52-week high of $5.91. Across his cross-ticker track record, his 6 prior sells achieved a 90-day well-timed rate of 50.00%, though at TSHA specifically, 2 of 3 prior measurable sells were well-timed at the 90-day mark. The company is unprofitable with a net income of $-32,733,000.00 over its most recent full fiscal year, though revenue growth was positive at +17.3% year-over-year. This sale by the company's R&D leader occurs as the stock trades well below its annual peak.

TSHA CEO Nolan sold 178,101 shares over two days for $840,196.07 at $4.72 avg; stock down 18.4% in 30 days.

Nolan Sean P., TSHA's Chief Executive Officer, executed 2 separate sales totaling 178,101 shares for $840,196.07 between January 23 and January 26, 2026, reducing holdings by 5.8% to 2,908,257 shares. The sales occurred at an average price of $4.72, close to the current price of $4.76, but follow a sharp 30-day decline of -18.4% and a broader 90-day decline of -5.0% from the 52-week high of $5.91. The company's recent fundamentals are stressed: Revenue stands at $0.00 for the latest quarter with annual revenue declining 46.1% year-over-year, and net income was $-32,733,000.00 over the full fiscal year. The CEO's prior trade at TSHA (a buy in August 2023) achieved positive returns at both the 30-day (+265.6%) and 90-day (+47.8%) marks, establishing a history of well-timed entries at this ticker, but this sale falls in a period of negative stock momentum and operational contraction.

Nagendran Sukumar (Pres./Head of R&D) sold 116,050 shares at avg $4.72 for $547,468.98; stock down 18.4% in 30 days post-sale.

Nagendran Sukumar, the company's President and Head of R&D, executed 2 separate sales totaling 116,050 shares for $547,468.98 on 2026-01-23 and 2026-01-26, reducing his holdings by 8.1% to 1.32M shares. The timing pattern is notable: Sukumar's prior TSHA sales on 2025-09-10, 2025-11-28, and 2025-12-01 were followed by 30-day gains ranging from +22.0% to +51.1%, suggesting his prior exits preceded further price appreciation. The current stock price is $4.76, down 18.4% over 30 days and 19.5% from its 52-week high of $5.91, indicating a sharp reversal since these January sales. The company remains unprofitable with $-32.7M net income and negative annual revenue growth of -46.1%, creating structural headwinds regardless of insider trading patterns. The divergence between Sukumar's recent timing (selling into apparent strength relative to current price weakness) and the subsequent market deterioration warrants attention.

TSHA President Nagendran Sukumar sells 200,000 shares at $4.71; stock down -12.5% in 30 days since Jan 12 sale.

Nagendran Sukumar, President and Head of R&D at Taysha Gene Therapies, sold 200,000 shares at $4.71 on 2026-01-12 for $942,000.00, reducing his holdings by 12.2% to 1,433,439 shares. At his prior two sales at this ticker (2025-12-01 and 2025-11-28), the stock rose 22.0% and 22.7% respectively over the following 30 days, but this sale has instead been followed by a -12.5% move in 30 days, indicating a reversal in the pattern observed just weeks earlier. The company remains unprofitable with $-32,733,000.00 net income in the most recent period and revenue declining 46.1% year-over-year, providing material context for executive equity decisions during ongoing operational challenges.

TSHA President Nagendran Sukumar sells 370,172 shares (370.2K shares) for $1,695,905.72 across 2 transactions at $4.75 and $4.51

Nagendran Sukumar, President and Head of R&D, executed 2 separate sales totaling 370,172 shares for $1,695,905.72, reducing his holdings by 26.9% from 1,376,611 to 1,006,439 shares. The sales occurred at $4.75 on 2025-11-28 and $4.51 on 2025-12-01, with a blended average price of $4.58, notably above the current market price of $4.43. The company faces significant operational headwinds: revenue is $0.00 for the latest quarter, net income stands at -$32,733,000.00, and annual revenue growth shows a decline of -46.1%. While Sukumar's cross-ticker track record demonstrates positive returns following his prior sells (avg 30d return +51.1%), his same-ticker history at TSHA is limited—only one prior sale on 2025-09-10 with a 30d outcome of +51.1%. The magnitude of this divestiture—removing over one-quarter of his holdings—combined with the company's deteriorating financial position and recent revenue contraction, warrants investor attention.

TSHA President Nagendran Sukumar sold 200,000 shares at $3.23 for $646,000; holds 1,006,439 shares post-sale amid unprofitable operations.

Nagendran Sukumar, President and Head of R&D, sold 200,000 shares at $3.23, reducing his holdings by 16.6% from 1.21M shares to 1.01M shares. Taysha Gene Therapies is deeply unprofitable with net income of $-26.9M and annual revenue decline of -46.1%, with latest quarterly revenue at $2.0M. The sale occurred while the stock trades at $3.07, near its 52-week high of $3.36, though the company's financial deterioration and steep revenue contraction raise questions about sustainability. An R&D leader's material stake reduction during a period of operational distress warrants investor scrutiny of pipeline progress and cash runway.

10% owner Manning Paul B purchases 750,000 shares of TSHA at $2.75 for $2.1M, raising stake to 2.84M shares (+35.9%).

Manning Paul B, a 10% owner, made an open-market purchase of 750,000 shares at $2.75 on 2025-05-30, increasing his total holdings from 2,091,704 shares to 2.84M shares—a 35.9% increase in his position. The stock has since risen 7.8% in the 30 days following the transaction and 63.5% over 90 days, though it remains -33.3% from its 52-week high of $4.17. Notably, his prior buy at TSHA on 2024-06-27 was followed by a 90-day decline of -10.7%, indicating a mixed historical track record at this ticker. The company is unprofitable (net income of $-21.5M in the latest quarter) with significant recent revenue contraction (-46.1% year-over-year), which frames this substantial accumulation against a deteriorating financial backdrop and suggests investors should monitor whether subsequent quarterly results validate or contradict the timing of this purchase.

10% Owner Manning Paul B purchases 1,333,333 shares of TSHA at $2.25 for $2,999,999.25; stock now -45.8% from 52-week high, unprofitable but growing revenue.

Manning Paul B, a 10% owner, invested approximately $3.0M in 1,333,333 shares at $2.25 on 2024-06-27, establishing a new position at TSHA. The stock has declined 45.8% from its 52-week high of $4.17 and is down 34.1% over 30 days and 16.6% over 90 days since the purchase. Taysha Gene Therapies is operationally unprofitable with a net loss of $24.1M in the latest full year, though revenue grew 517.6% year-over-year to $3.4M in the most recent quarter. Manning's cross-ticker track record shows strong timing discipline (75% win rate at 90 days with +188.6% average return), but his prior TSHA trades were mixed: one gained 265.6% at 30 days while another was flat; only 1 of 2 prior TSHA trades was well-timed at the 90-day mark. This purchase occurs during a period of significant downward price momentum in an unprofitable biotech, warranting close attention to how this position develops relative to the company's path to profitability.